Log in

NYSE:MNK - Mallinckrodt Stock Price, Forecast & News

$1.98
-0.27 (-12.00 %)
(As of 04/1/2020 03:54 AM ET)
Today's Range
$1.83
Now: $1.98
$2.39
50-Day Range
$1.08
MA: $3.37
$5.43
52-Week Range
$1.00
Now: $1.98
$23.90
Volume6.65 million shs
Average Volume8.82 million shs
Market Capitalization$166.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.39
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom.
Read More
Mallinckrodt logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-0-17-8463-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.16 billion
Cash Flow$18.00 per share
Book Value$23.08 per share

Profitability

Net Income$-996,500,000.00

Miscellaneous

Employees3,400
Market Cap$166.73 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.


Mallinckrodt (NYSE:MNK) Frequently Asked Questions

How has Mallinckrodt's stock been impacted by COVID-19 (Coronavirus)?

Mallinckrodt's stock was trading at $3.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MNK stock has decreased by 35.1% and is now trading at $1.98. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mallinckrodt?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 2 sell ratings, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Mallinckrodt.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Mallinckrodt.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) issued its quarterly earnings data on Tuesday, February, 25th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.05 by $0.35. The firm had revenue of $804.90 million for the quarter, compared to analyst estimates of $771.73 million. Mallinckrodt had a negative net margin of 31.51% and a positive return on equity of 27.05%. The business's revenue for the quarter was down 3.6% on a year-over-year basis. During the same quarter last year, the business posted $2.18 earnings per share. View Mallinckrodt's earnings history.

What price target have analysts set for MNK?

15 equities research analysts have issued twelve-month price objectives for Mallinckrodt's stock. Their forecasts range from $2.00 to $22.00. On average, they anticipate Mallinckrodt's stock price to reach $8.27 in the next year. This suggests a possible upside of 317.5% from the stock's current price. View analysts' price targets for Mallinckrodt.

Has Mallinckrodt been receiving favorable news coverage?

Press coverage about MNK stock has been trending very negative this week, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mallinckrodt earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View the latest news aboutMallinckrodt.

Are investors shorting Mallinckrodt?

Mallinckrodt saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 53,754,700 shares, an increase of 10.9% from the February 27th total of 48,480,000 shares. Based on an average daily trading volume, of 7,800,000 shares, the short-interest ratio is presently 6.9 days. Currently, 65.7% of the shares of the company are sold short. View Mallinckrodt's Current Options Chain.

Who are some of Mallinckrodt's key competitors?

What other stocks do shareholders of Mallinckrodt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Micron Technology (MU), Gilead Sciences (GILD), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Endo International (ENDP), Gerdau (GGB), Celgene (CELG), Alibaba Group (BABA), Skyworks Solutions (SWKS) and AT&T (T).

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the following people:
  • Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
  • Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
  • Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)
  • Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
  • Mr. Bryan M. Reasons, Chief Financial Officer (Age 52)

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $1.98.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $166.73 million and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis. Mallinckrodt employs 3,400 workers across the globe. View additional information about Mallinckrodt.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is http://www.mallinckrodt.com/.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]


MarketBeat Community Rating for Mallinckrodt (NYSE MNK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  979 (Vote Outperform)
Underperform Votes:  604 (Vote Underperform)
Total Votes:  1,583
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel